Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and Equipment
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TKPHF) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Takeda Pharmaceutical (TKPHF) over the last 8 years, with Q4 2025 value amounting to -$71.0 million.

  • Takeda Pharmaceutical's Change in Receivables fell 18522.5% to -$71.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $104.0 million, marking a year-over-year decrease of 5002.79%. This contributed to the annual value of -$387.1 million for FY2025, which is 46956.55% down from last year.
  • Takeda Pharmaceutical's Change in Receivables amounted to -$71.0 million in Q4 2025, which was down 18522.5% from -$66.5 million recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Change in Receivables registered a high of $1.2 billion during Q4 2021, and its lowest value of -$659.4 million during Q2 2023.
  • Over the past 5 years, Takeda Pharmaceutical's median Change in Receivables value was $85.3 million (recorded in 2024), while the average stood at $95.0 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 36120.62% in 2021, then crashed by 37458.81% in 2023.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Change in Receivables stood at $1.2 billion in 2021, then tumbled by 92.52% to $90.4 million in 2022, then grew by 6.93% to $96.7 million in 2023, then dropped by 13.75% to $83.4 million in 2024, then crashed by 185.23% to -$71.0 million in 2025.
  • Its Change in Receivables was -$71.0 million in Q4 2025, compared to -$66.5 million in Q3 2025 and $332.3 million in Q2 2025.